Abstract 592P
Background
Mesenchymal–epithelial transition factor (MET) exon 14 (METex14) skipping is an established primary oncogenic driver in non-small cell lung cancer (NSCLC). Specific inhibition of METex14 skipping by targeted therapy can achieve durable responses. As targeted therapies are gradually becoming available to patients with METex14 skipping NSCLC in China, this study aims to assess the emerging characteristics, treatment patterns, and clinical outcomes in these patients.
Methods
This non-interventional study retrospectively reviewed existing medical records. The National Anti-Tumor Drug Surveillance System (NATDSS), a nationwide cancer database, was used to identify patients diagnosed with advanced NSCLC harboring METex14 skipping alterations between 2013 and 2021. Descriptive statistics were used to summarize patient characteristics and treatment patterns. Kaplan–Meier analyses were employed to describe overall survival (OS).
Results
A total of 297 patients were included in the study. The median age was 67 years (range: 61–72 years) and 154 patients (51.9%) were male. Adenocarcinoma (226 [76.1%]) was the most frequent histology documented. Of note, 16 (5.4%) had sarcomatoid carcinoma. At diagnosis, 44 patients (14.8%) had Stage IIIB–C and 253 patients (85.2%) had Stage IV disease, among which 48 patients (16.2%) had brain metastases. Among 236 (79.5%) patients who received systemic treatment after the diagnosis of advanced NSCLC, the most frequent first-line therapies were chemotherapy (97 [32.7%]), followed by MET inhibitors (81 [27.3%]) and chemotherapy plus immune checkpoint inhibitor (16 [5.4%]). Median OS was 16.1 months (95% CI: 13.7, 18.7) from start of first-line therapy for the entire cohort, and 8.9 months (5.7–NE) for patients with sarcomatoid carcinoma.
Conclusions
METex14 skipping alterations typically occur in elderly patients and in adenocarcinomas in the Chinese population. Treatment patterns were heterogeneous, with a large proportion of patients receiving chemotherapy with or without MET inhibitors, reflecting the evolving treatment landscape in China.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Merck Healthcare KGaA, Darmstadt, Germany.
Funding
Merck (CrossRef Funder ID: 10.13039/100009945).
Disclosure
C. Chen, Y. Zhang: Financial Interests, Personal, Full or part-time Employment: Merck Serono Co., Ltd., Beijing, China, an affiliate of Merck KGaA. H. Vioix: Financial Interests, Personal, Full or part-time Employment: Merck. All other authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract